Henrik Hasle

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9085078/publications.pdf

Version: 2024-02-01

290 papers	13,457 citations	22153 59 h-index	25787 108 g-index
300 all docs	300 docs citations	300 times ranked	10955 citing authors

#	Article	IF	Citations
1	Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nature Genetics, 2003, 34, 148-150.	21.4	960
2	Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet, The, 2000, 355, 165-169.	13.7	746
3	Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood, 2012, 120, 3187-3205.	1.4	451
4	A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia, 2003, 17, 277-282.	7.2	397
5	Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood, 2009, 114, 2489-2496.	1.4	383
6	Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Blood, 1997, 89, 3534-43.	1.4	320
7	Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nature Genetics, 2010, 42, 794-800.	21.4	308
8	Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. Blood, 2016, 127, 1387-1397.	1.4	304
9	Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood, 2005, 105, 410-419.	1.4	291
10	Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. Journal of Clinical Oncology, 2015, 33, 2949-2962.	1.6	277
11	Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood, 2009, 114, 1859-1863.	1.4	260
12	Pattern of malignant disorders in individuals with Down's syndrome. Lancet Oncology, The, 2001, 2, 429-436.	10.7	255
13	The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood, 2005, 106, 2183-2185.	1.4	247
14	Cancer incidence in men with Klinefelter syndrome. British Journal of Cancer, 1995, 71, 416-420.	6.4	222
15	Improved Outcome in Pediatric Relapsed Acute Myeloid Leukemia: Results of a Randomized Trial on Liposomal Daunorubicin by the International BFM Study Group. Journal of Clinical Oncology, 2013, 31, 599-607.	1.6	197
16	RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia, 1999, 13, 32-37.	7.2	186
17	Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2011, 157, 83-89.	1.6	176
18	Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 3339-3344.	7.1	173

#	Article	IF	Citations
19	WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study. British Journal of Haematology, 2004, 125, 590-600.	2.5	171
20	Response-Guided Induction Therapy in Pediatric Acute Myeloid Leukemia With Excellent Remission Rate. Journal of Clinical Oncology, 2011, 29, 310-315.	1.6	156
21	Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7. Blood, 2003, 102, 1997-2003.	1.4	154
22	Long-term results in children with AML: NOPHO-AML Study Group â€“ report of three consecutive trials. Leukemia, 2005, 19, 2090-2100.	7.2	144
23	Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7. Leukemia, 1999, 13, 376-385.	7.2	142
24	Childhood cancer: Survival, treatment modalities, late effects and improvements over time. Cancer Epidemiology, 2021, 71, 101733.	1.9	136
25	Acute leukaemia in children with Down syndrome: a population-based Nordic study. British Journal of Haematology, 2005, 128, 797-804.	2.5	132
26	Low risk of solid tumors in persons with Down syndrome. Genetics in Medicine, 2016, 18, 1151-1157.	2.4	129
27	Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. Blood, 2007, 109, 4641-4647.	1.4	126
28	Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood, 2010, 115, 198-205.	1.4	125
29	Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on Myelodysplastic Syndrome in Childhood.. Journal of Clinical Oncology, 1997, 15, 566-573.	1.6	110
30	Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trials. British Journal of Haematology, 2003, 122, 217-225.	2.5	110
31	Occurrence of cancer in women with Turner syndrome. British Journal of Cancer, 1996, 73, 1156-1159.	6.4	101
32	A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada. British Journal of Haematology, 1999, 106, 1027-1032.	2.5	100
33	Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome. Blood, 2010, 116, 3766-3769.	1.4	99
34	Myelodysplastic Syndromes in Childhoodâ€"Classification, Epidemiology, and Treatment. Leukemia and Lymphoma, 1994, 13, 11-26.	1.3	97
35	Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004. Blood, 2012, 120, 978-984.	1.4	97
36	Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome. Blood, 2011, 117, 4871-4880.	1.4	94

#	Article	IF	Citations
37	Childhood myelodysplastic syndrome in Denmark: incidence and predisposing conditions. Leukemia, 1995, 9, 1569-72.	7.2	92
38	The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). Leukemia, 2004, 18, 2008-2014.	7.2	91
39	RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia. Nature Communications, 2017, 8, 2126.	12.8	91
40	Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-MÃ¼nster AML-study group. Blood, 2013, 122, 2704-2713.	1.4	86
41	Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia. Blood, 2011, 118, 5905-5913.	1.4	83
42	Constitutional SAMD9L mutations cause familial myelodysplastic syndrome and transient monosomy 7. Haematologica, 2018, 103, 427-437.	3.5	83
43	Improved outcome after relapse in children with acute myeloid leukaemia. British Journal of Haematology, 2007, 136, 229-236.	2.5	81
44	Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia. Leukemia, 2005, 19, 971-977.	7.2	80
45	Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes. Nature Medicine, 2021, 27, 1806-1817.	30.7	79
46	t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients. Haematologica, 2014, 99, 865-872.	3.5	77
47	Mediastinal germ cell tumour associated with Klinefelter syndrome. European Journal of Pediatrics, 1992, 151, 735-739.	2.7	75
48	Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. British Journal of Haematology, 2010, 148, 768-776.	2.5	75
49	Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. British Journal of Haematology, 2008, 141, 782-791.	2.5	71
50	A Summary of the Inaugural WHO Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular Era. Cancer Discovery, 2022, 12, 331-355.	9.4	70
51	Hospital contacts for endocrine disorders in Adult Life after Childhood Cancer in Scandinavia (ALiCCS): a population-based cohort study. Lancet, The, 2014, 383, 1981-1989.	13.7	69
52	Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study. Blood, 2015, 126, 1575-1584.	1.4	69
53	Classification of treatment-related mortality in children with cancer: a systematic assessment. Lancet Oncology, The, 2015, 16, e604-e610.	10.7	69
54	Evidence of decreased risk of cancer in individuals with fragile X. American Journal of Medical Genetics Part A, 2001, 103, 226-230.	2.4	65

#	Article	IF	Citations
55	Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML. Blood, 2012, 119, e96-e99.	1.4	65
56	Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the <scp>NOPHO</scp>â€<scp>AML</scp> 2004 study. British Journal of Haematology, 2016, 174, 600-609.	2.5	65
57	Malignant Diseases in Noonan Syndrome and Related Disorders. Hormone Research, 2009, 72, 8-14.	1.8	64
58	Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial. Blood, 2017, 129, 3314-3321.	1.4	64
59	Surviving childhood cancer: a systematic review of studies on risk and determinants of adverse socioeconomic outcomes. International Journal of Cancer, 2019, 144, 1796-1823.	5.1	64
60	Nationwide germline whole genome sequencing of 198 consecutive pediatric cancer patients reveals a high incidence of cancer prone syndromes. PLoS Genetics, 2020, 16, e1009231.	3.5	64
61	Long-term inpatient disease burden in the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study: A cohort study of 21,297 childhood cancer survivors. PLoS Medicine, 2017, 14, e1002296.	8.4	64
62	Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML. Leukemia, 2008, 22, 1428-1430.	7.2	63
63	A critical review of which children with acute myeloid leukaemia need stem cell procedures. British Journal of Haematology, 2014, 166, 23-33.	2.5	62
64	Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature. Annals of Hematology, 2006, 85, 275-280.	1.8	61
65	Adult Life after Childhood Cancer in Scandinavia: Diabetes mellitus following treatment for cancer in childhood. European Journal of Cancer, 2014, 50, 1169-1175.	2.8	61
66	Cardiovascular disease in Adult Life after Childhood Cancer in <scp>S</scp>candinavia: A populationâ€based cohort study of 32,308 oneâ€year survivors. International Journal of Cancer, 2015, 137, 1176-1186.	5.1	61
67	Genotype-phenotype correlation in cases of juvenile myelomonocytic leukemia with clonal RAS mutations. Blood, 2008, 111, 966-967.	1.4	60
68	Advances in the prognostication and management of advanced MDS in children. British Journal of Haematology, 2011, 154, 185-195.	2.5	60
69	Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group. Blood, 2015, 125, 2311-2313.	1.4	60
70	Minimal residual core binding factor AMLs by real time quantitative PCRâ€”Initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse. Leukemia Research, 2006, 30, 389-395.	0.8	59
71	Mitotic recombination and compound-heterozygous mutations are predominant NF1-inactivating mechanisms in children with juvenile myelomonocytic leukemia and neurofibromatosis type 1. Haematologica, 2010, 95, 320-323.	3.5	58
72	Myelodysplastic and myeloproliferative disorders of childhood. Hematology American Society of Hematology Education Program, 2016, 2016, 598-604.	2.5	57

#	Article	IF	Citations
73	Myelodysplastic syndrome in a child with constitutional trisomy 8 mosaicism and normal phenotype. Cancer Genetics and Cytogenetics, 1995, 79, 79-81.	1.0	54
74	Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia. Leukemia, 1996, 10, 1269-73.	7.2	52
75	Myelodysplastic and myeloproliferative disorders in children. Current Opinion in Pediatrics, 2007, 19, 1-8.	2.0	48
76	LIN28B overexpression defines a novel fetal-like subgroup of juvenile myelomonocytic leukemia. Blood, 2016, 127, 1163-1172.	1.4	48
77	Early and treatmentâ€related deaths in childhood acute myeloid leukaemia in the Nordic countries: 1984â€“2003. British Journal of Haematology, 2010, 151, 447-459.	2.5	47
78	Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL. Blood, 2018, 132, 405-412.	1.4	46
79	The Adult Life After Childhood Cancer in Scandinavia (ALiCCS) Study: Design and Characteristics. Pediatric Blood and Cancer, 2015, 62, 2204-2210.	1.5	45
80	Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group. Blood, 2018, 132, 1584-1592.	1.4	45
81	Arthritis as presenting manifestation of acute lymphoblastic leukaemia in children. Archives of Disease in Childhood, 2015, 100, 821-825.	1.9	44
82	Quality of health in survivors of childhood acute myeloid leukemia treated with chemotherapy only: A NOPHOâ€AML study. Pediatric Blood and Cancer, 2011, 57, 1222-1229.	1.5	43
83	Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia. Haematologica, 2015, 100, 17-22.	3.5	43
84	The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: results of the international study Relapsed AML 2001/01. Haematologica, 2014, 99, 1472-1478.	3.5	42
85	Bone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood. Haematologica, 2015, 100, 315-323.	3.5	38
86	Extramedullary leukemia in children with acute myeloid leukemia: A populationâ€based cohort study from the Nordic Society of Pediatric Hematology and Oncology (NOPHO). Pediatric Blood and Cancer, 2017, 64, e26520.	1.5	38
87	Synonymous GATA2 mutations result in selective loss of mutated RNA and are common in patients with GATA2 deficiency. Leukemia, 2020, 34, 2673-2687.	7.2	38
88	Comparison of horse and rabbit antithymocyte globulin in immunosuppressive therapy for refractory cytopenia of childhood. Haematologica, 2014, 99, 656-663.	3.5	36
89	Genetic and epigenetic similarities and differences between childhood and adult AML. Pediatric Blood and Cancer, 2012, 58, 525-531.	1.5	34
90	RASA4undergoes DNA hypermethylation in resistant juvenile myelomonocytic leukemia. Epigenetics, 2014, 9, 1252-1260.	2.7	34

#	Article	IF	Citations
91	Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: a retrospective, international study. Haematologica, 2014, 99, 299-307.	3.5	34
92	Hospitalizations among people with Down syndrome: A nationwide populationâ€based study in Denmark. American Journal of Medical Genetics, Part A, 2013, 161, 650-657.	1.2	32
93	Effect of age and body weight on toxicity and survival in pediatric acute myeloid leukemia: results from NOPHO-AML 2004. Haematologica, 2016, 101, 1359-1367.	3.5	32
94	Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy. Annals of Hematology, 2017, 96, 1449-1456.	1.8	32
95	Gastrointestinal toxicity during induction treatment for childhood acute lymphoblastic leukemia: The impact of the gut microbiota. International Journal of Cancer, 2020, 147, 1953-1962.	5.1	32
96	Transient pancytopenia preceding acute lymphoblastic leukemia (pre-ALL). Leukemia, 1995, 9, 605-8.	7.2	32
97	Therapy with lowâ€dose azacitidine for <scp>MDS</scp> in children and young adults: a retrospective analysis of the <scp>EWOG</scp>â€<scp>MDS</scp> study group. British Journal of Haematology, 2016, 172, 930-936.	2.5	31
98	Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study. European Journal of Cancer, 2020, 138, 212-224.	2.8	31
99	Janus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Down's syndrome. Leukemia, 2007, 21, 1584-1587.	7.2	30
100	Outcome after intensive reinduction therapy and allogeneic stem cell transplant in paediatric relapsed acute myeloid leukaemia. British Journal of Haematology, 2017, 178, 592-602.	2.5	30
101	Impaired CD163-mediated hemoglobin-scavenging and severe toxic symptoms in patients treated with gemtuzumab ozogamicin. Blood, 2008, 112, 1510-1514.	1.4	29
102	Ploidy and clinical characteristics of childhood acute myeloid leukemia: A NOPHOâ€AML study. Genes Chromosomes and Cancer, 2014, 53, 667-675.	2.8	28
103	Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study. Pharmacogenomics Journal, 2020, 20, 294-305.	2.0	28
104	Chronic parvovirus infection mimicking myelodysplastic syndrome in a child with subclinical immunodeficiency. The American Journal of Pediatric Hematology/oncology, 1994, 16, 329-33.	1.3	28
105	Mutation analysis of Son of Sevenless in juvenile myelomonocytic leukemia. Leukemia, 2007, 21, 1108-1109.	7.2	26
106	Pubertal development and fertility in survivors of childhood acute myeloid leukemia treated with chemotherapy only: A NOPHO-AML study. Pediatric Blood and Cancer, 2013, 60, 1988-1995.	1.5	25
107	High frequency of streptococcal bacteraemia during childhood AML therapy irrespective of dose of cytarabine. Pediatric Blood and Cancer, 2013, 60, 1154-1160.	1.5	25
108	Acute myeloid leukemia (AML) with t(7;12)(q36;p13) is associated with infancy and trisomy 19: Data from Nordic Society for Pediatric Hematology and Oncology (NOPHOâ€AML) and review of the literature. Genes Chromosomes and Cancer, 2018, 57, 359-365.	2.8	25

#	Article	IF	Citations
109	Hematopoietic stem cell transplantation in children and adolescents with GATA2-related myelodysplastic syndrome. Bone Marrow Transplantation, 2021, 56, 2732-2741.	2.4	24
110	Long-term health outcomes in survivors of childhood AML treated with allogeneic HSCT: a NOPHOâ€“AML Study. Bone Marrow Transplantation, 2019, 54, 726-736.	2.4	23
111	Cancer in relatives of children with myelodysplastic syndrome, acute and chronic myeloid leukaemia. British Journal of Haematology, 1997, 97, 127-131.	2.5	22
112	Pediatric myelodysplastic syndromes. Current Treatment Options in Oncology, 2005, 6, 209-214.	3.0	22
113	Prolonged intrathecal chemotherapy replacing cranial irradiation in high-risk acute lymphatic leukaemia: Long-term follow up with cerebral computed tomography scans and endocrinological studies. European Journal of Pediatrics, 1995, 154, 24-29.	2.7	21
114	Occurrence of Cancer in a Cohort of 183 Persons with Constitutional Chromosome 7 Abnormalities. Cancer Genetics and Cytogenetics, 1998, 105, 39-42.	1.0	21
115	The clinical relevance of minor paroxysmal nocturnal hemoglobinuria clones in refractory cytopenia of childhood: a prospective study by EWOG-MDS. Leukemia, 2014, 28, 189-192.	7.2	21
116	Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators. Blood Cancer Discovery, 2021, 2, 586-599.	5.0	21
117	Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia. Leukemia, 2011, 25, 1365-1368.	7.2	20
118	Applicability of a reproducible flow cytometry scoring system in the diagnosis of refractory cytopenia of childhood. Leukemia, 2013, 27, 1923-1925.	7.2	20
119	Extreme doses of intravenous methadone for severe pain in two children with cancer. Pediatric Blood and Cancer, 2015, 62, 1087-1090.	1.5	20
120	FAMily-Oriented Support (FAMOS): development and feasibility of a psychosocial intervention for families of childhood cancer survivors. Acta OncolÃ³gica, 2017, 56, 367-374.	1.8	19
121	Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia. British Journal of Haematology, 2020, 190, 198-208.	2.5	19
122	The applicability of the <scp>WHO</scp> classification in paediatric <scp>AML</scp>. A <scp>NOPHO</scp>â€<scp>AML</scp> study. British Journal of Haematology, 2015, 169, 859-867.	2.5	18
123	Effects of a physical activity program from diagnosis on cardiorespiratory fitness in children with cancer: a national non-randomized controlled trial. BMC Medicine, 2020, 18, 175.	5.5	18
124	Incidence of Severe Osteonecrosis Requiring Total Joint Arthroplasty in Children and Young Adults Treated for Leukemia or Lymphoma: A Nationwide, Register-Based Study in Finland and Denmark. Journal of Adolescent and Young Adult Oncology, 2013, 2, 138-144.	1.3	17
125	Cardiac function in survivors of childhood acute myeloid leukemia treated with chemotherapy only: a <scp>NOPHO</scp>â€<scp>AML</scp> study. European Journal of Haematology, 2016, 97, 55-62.	2.2	17
126	Autoimmune diseases in Adult Life after Childhood Cancer in Scandinavia (ALiCCS). Annals of the Rheumatic Diseases, 2016, 75, 1622-1629.	0.9	17

#	Article	IF	Citations
127	Hodgkin's disease diagnosed post mortem: a population based study. British Journal of Cancer, 1993, 67, 185-189.	6.4	16
128	Renal, gastrointestinal, and hepatic late effects in survivors of childhood acute myeloid leukemia treated with chemotherapy only-A NOPHO-AML study. Pediatric Blood and Cancer, 2014, 61, 1638-1643.	1.5	16
129	Acute Myeloid Leukemia in Adolescents and Young Adults Treated in Pediatric and Adult Departments in the Nordic Countries. Pediatric Blood and Cancer, 2016, 63, 83-92.	1.5	16
130	Incidence and survival of childhood central nervous system tumors in Denmark, 1997â€“2019. Cancer Medicine, 2021, , .	2.8	16
131	A novel somatic K-Ras mutation in juvenile myelomonocytic leukemia. Leukemia, 2006, 20, 1637-1638.	7.2	15
132	Long-term risk of renal and urinary tract diseases in childhood cancer survivors: A population-based cohort study. European Journal of Cancer, 2016, 64, 52-61.	2.8	15
133	Strategies for reducing the treatmentâ€related physical burden of childhood acute myeloid leukaemia â€“ a review. British Journal of Haematology, 2017, 176, 168-178.	2.5	15
134	Somatic late effects in 5â€year survivors of neuroblastoma: a populationâ€based cohort study within the Adult Life after Childhood Cancer in Scandinavia study. International Journal of Cancer, 2018, 143, 3083-3096.	5.1	15
135	Germline GATA1s-generating mutations predispose toÂleukemia with acquired trisomy 21 and Down syndrome-like phenotype. Blood, 2022, 139, 3159-3165.	1.4	15
136	Characteristics and outcome in patients with central nervous system involvement treated in European pediatric acute myeloid leukemia study groups. Pediatric Blood and Cancer, 2017, 64, e26664.	1.5	14
137	Age and Prognosis in Pediatric AML. Blood, 2008, 112, 2990-2990.	1.4	14
138	GATA1 Mutation Analysis Demonstrates Two Distinct Primary Leukemias in a Child With Down Syndrome; Implications for Leukemogenesis. Journal of Pediatric Hematology/Oncology, 2005, 27, 408-409.	0.6	13
139	Thioguanine pharmacokinetics in induction therapy of children with acute myeloid leukemia. Anti-Cancer Drugs, 2009, 20, 7-14.	1.4	13
140	Mitochondrial 12S Ribosomal RNA A1555G Mutation Associated with Cardiomyopathy and Hearing Loss following High-Dose Chemotherapy and Repeated Aminoglycoside Exposure. Journal of Pediatrics, 2014, 164, 413-415.	1.8	13
141	Is it possible to cure childhood acute myeloid leukaemia without significant cardiotoxicity?. British Journal of Haematology, 2016, 175, 577-587.	2.5	13
142	Characteristics of children with acute lymphoblastic leukemia presenting with arthropathy. Clinical Rheumatology, 2018, 37, 2455-2463.	2.2	13
143	Risk of cardiovascular disease among Nordic childhood cancer survivors with diabetes mellitus: A report from adult life after childhood cancer in Scandinavia. Cancer, 2018, 124, 4393-4400.	4.1	13
144	The long non-coding RNA landscape in juvenile myelomonocytic leukemia. Haematologica, 2018, 103, e501-e504.	3.5	13

#	Article	IF	Citations
145	Neurologic disorders in 4858 survivors of central nervous system tumors in childhoodâ€”an Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study. Neuro-Oncology, 2019, 21, 125-136.	1.2	13
146	WT1 gene expression in children with Down syndrome and transient myeloproliferative disorder. Leukemia Research, 2006, 30, 543-546.	0.8	12
147	Outcome of poor response paediatric <scp>AML</scp> using early <scp>SCT</scp>. European Journal of Haematology, 2013, 90, 187-194.	2.2	12
148	Gastrointestinal and liver disease in Adult Life After Childhood Cancer in Scandinavia: A populationâ€based cohort study. International Journal of Cancer, 2016, 139, 1501-1511.	5.1	12
149	Hyperleucocytosis in paediatric acute myeloid leukaemia â€“ the challenge of white blood cell counts above 200ÂÂ—Â10⁹/l. The <scp>NOPHO</scp> experience 1984â€“2014. British Journal of Haematology, 2017, 178, 448-456.	2.5	12
150	Identifying acute lymphoblastic leukemia mimicking juvenile idiopathic arthritis in children. PLoS ONE, 2020, 15, e0237530.	2.5	12
151	Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective Iâ€BFM analysis of 333 children. British Journal of Haematology, 2020, 189, 745-750.	2.5	12
152	Association of unbalanced translocation der(1;7) with germline GATA2 mutations. Blood, 2021, 138, 2441-2445.	1.4	12
153	Anthracycline Type during Induction Associated with Outcome in Pediatric t(8;21) and Inv(16) AML. Blood, 2014, 124, 11-11.	1.4	12
154	Complex Three-Way Translocation Involving <i>MLL</i>, <i>ELL</i>, <i>RREB1</i>, and <i>CMAHP </i>Genes in an Infant with Acute Myeloid Leukemia and t(6;19;11)(p22.2;p13.1;q23.3). Cytogenetic and Genome Research, 2013, 141, 7-15.	1.1	11
155	Presenting features and imaging in childhood acute myeloid leukemia with central nervous system involvement. Pediatric Blood and Cancer, 2017, 64, e26459.	1.5	11
156	Long-Term Risk of Hospitalization Among Five-Year Survivors of Childhood Leukemia in the Nordic Countries. Journal of the National Cancer Institute, 2019, 111, 943-951.	6.3	11
157	Peripheral blood molecular measurable residual disease is sufficient to identify patients with acute myeloid leukaemia with imminent clinical relapse. British Journal of Haematology, 2021, 195, 310-327.	2.5	11
158	SLC25A38 congenital sideroblastic anemia: Phenotypes and genotypes of 31 individuals from 24 families, including 11 novel mutations, and a review of the literature. Human Mutation, 2021, 42, 1367-1383.	2.5	11
159	Haemophagocytic lymphohistiocytosis associated with constitutional inversion of chromosome 9. British Journal of Haematology, 1996, 93, 808-809.	2.5	10
160	High frequency of copy number alterations in myeloid leukaemia of <scp>D</scp>own syndrome. British Journal of Haematology, 2012, 158, 800-803.	2.5	10
161	Trisomy 8 in pediatric acute myeloid leukemia: A NOPHOâ€AML study. Genes Chromosomes and Cancer, 2016, 55, 719-726.	2.8	10
162	Late mortality and morbidity among longâ€term leukemia survivors with Down syndrome: A nationwide populationâ€based cohort study. Pediatric Blood and Cancer, 2018, 65, e27249.	1.5	10

#	Article	IF	Citations
163	Use of granulocyte colonyâ€stimulating factor and risk of relapse in pediatric patients treated for acute myeloid leukemia according to NOPHOâ€AML 2004 and DB AMLâ€01. Pediatric Blood and Cancer, 2019, 66, e27701.	1.5	10
164	Somatic Genetic and Epigenetic Architecture of Myelodysplastic Syndromes Arising from GATA2 Deficiency. Blood, 2015, 126, 299-299.	1.4	10
165	Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study. JMIR Research Protocols, 2019, 8, e11868.	1.0	10
166	Homeâ€based cognitive behavioural therapy for families of young children with cancer (FAMOS): A nationwide randomised controlled trial. Pediatric Blood and Cancer, 2021, 68, e28853.	1.5	10
167	Treatmentâ€related deaths in second complete remission in childhood acute myeloid leukaemia. British Journal of Haematology, 2011, 152, 623-630.	2.5	9
168	Cancer Screening in Li-Fraumeni Syndrome. JAMA Oncology, 2017, 3, 1645.	7.1	9
169	Congenital hypoplastic bone marrow failure associated with a de novo partial deletion of the MECOM gene at 3q26.2. Gene, 2018, 656, 86-94.	2.2	9
170	Measurable residual disease monitoring using Wilms tumor gene 1 expression in childhood acute myeloid leukemia based on childâ€specific reference values. Pediatric Blood and Cancer, 2019, 66, e27671.	1.5	9
171	COVIDâ€19 â€“ Impact on Childhood Haematology Patients. HemaSphere, 2020, 4, e465.	2.7	9
172	Clonal Mutational Landscape of Childhood Myelodysplastic Syndromes. Blood, 2015, 126, 1662-1662.	1.4	9
173	Psychiatric disorders in childhood cancer survivors in Denmark, Finland, and Sweden: a register-based cohort study from the SALiCCS research programme. Lancet Psychiatry,the, 2022, 9, 35-45.	7.4	9
174	Acute Respiratory Failure in 3 Children With Juvenile Myelomonocytic Leukemia. Journal of Pediatric Hematology/Oncology, 2011, 33, e363-e367.	0.6	8
175	T-cell receptor VÎ² skewing frequently occurs in refractory cytopenia of childhood and is associated with an expansion of effector cytotoxic T cells: a prospective study by EWOG-MDS. Blood Cancer Journal, 2014, 4, e209-e209.	6.2	8
176	Complex and monosomal karyotype are distinct cytogenetic entities with an adverse prognostic impact in paediatric acute myeloid leukaemia. A <scp>NOPHO</scp>â€<scp>DBH</scp>â€<scp>AML</scp> study. British Journal of Haematology, 2018, 183, 618-628.	2.5	8
177	Associations between neutrophil recovery time, infections and relapse in pediatric acute myeloid leukemia. Pediatric Blood and Cancer, 2018, 65, e27231.	1.5	8
178	Differences in infection prophylaxis measures between paediatric acute myeloid leukaemia study groups within the international Berlinâ€“FrankfÃ¼rtâ€“MÃ¼nster (Iâ€<scp>BFM</scp>) study group. British Journal of Haematology, 2018, 183, 87-95.	2.5	8
179	Associations between pretherapeutic body mass index, outcome, and cytogenetic abnormalities in pediatric acute myeloid leukemia. Cancer Medicine, 2019, 8, 6634-6643.	2.8	8
180	Hyperthyroidism as a late effect in childhood cancer survivors - an Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study. Acta OncolÃ³gica, 2019, 58, 227-231.	1.8	8

#	Article	IF	Citations
181	Neurologic disorders in long-term survivors of neuroblastoma â€“ a population-based cohort study within the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) research program. Acta OncolÃ³gica, 2020, 59, 134-140.	1.8	8
182	DNA Methylation Signatures Predict Cytogenetic Subtype and Outcome in Pediatric Acute Myeloid Leukemia (AML). Genes, 2021, 12, 895.	2.4	8
183	TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. Npj Precision Oncology, 2021, 5, 64.	5.4	8
184	Hepatotoxicity in Patients Treated with Gemtuzumab Ozogamicin - Specific Targeting of Hepatocytes?. Blood, 2009, 114, 4150-4150.	1.4	8
185	ATYPICAL CHRONIC MYELOID LEUKAEMIA AND CHRONIC MYELOMONOCYTIC LEUKAEMIA IN CHILDREN. British Journal of Haematology, 1995, 89, 428-429.	2.5	7
186	Response: high ERG gene expression is an unfavorable prognostic marker in pediatric acute myeloid leukemia. Blood, 2012, 119, 1087-1088.	1.4	7
187	Skeletal adverse events in childhood cancer survivors: An Adult Life after Childhood Cancer in Scandinavia cohort study. International Journal of Cancer, 2021, 149, 1863-1876.	5.1	7
188	Unexpected High Frequency of GATA2 Mutations in Children with Non-Familial MDS and Monosomy 7. Blood, 2012, 120, 1699-1699.	1.4	7
189	Employment status and occupational positions of childhood cancer survivors from Denmark, Finland and Sweden: A Nordic register-based cohort study from the SALiCCS research programme. Lancet Regional Health - Europe, The, 2022, 12, 100258.	5.6	7
190	A novel splice mutation in theTP53 gene associated with Leydig cell tumor and primitive neuroectodermal tumor. Pediatric Blood and Cancer, 2008, 50, 701-703.	1.5	6
191	Refractory Cytopenia In Childhood (RCC) with Normal Karyotype Is Unlikely to Progress to Advanced MDS Under a Watch and Wait Strategy. Blood, 2010, 116, 4007-4007.	1.4	6
192	Translocation t(6;9)(p22;q34)/DEK-NUP214 rearranged Pediatric AML: A Retrospective International Study. Blood, 2012, 120, 538-538.	1.4	6
193	Clinical characteristics and registry-validated extended pedigrees of germline TP53 mutation carriers in Denmark. PLoS ONE, 2018, 13, e0190050.	2.5	6
194	Cohort Profile: The Socioeconomic Consequences in Adult Life After Childhood Cancer in Scandinavia (SALiCCS) Research Programme. Frontiers in Oncology, 2021, 11, 752948.	2.8	6
195	Late mortality among survivors of childhood acute lymphoblastic leukemia diagnosed during 1971â€“2008 in Denmark, Finland, and Sweden: A populationâ€based cohort study. Pediatric Blood and Cancer, 2022, 69, e29356.	1.5	5
196	Prognostic significance of chromosomal abnormalities at relapse in children with relapsed acute myeloid leukemia: A retrospective cohort study of the Relapsed AML 2001/01 Study. Pediatric Blood and Cancer, 2022, 69, e29341.	1.5	5
197	Gemtuzumab Ozogamicin as Post-Consolidation Therapy Does Not Prevent Relapse In Children with AML. Results of the NOPHO-AML 2004 Study. Blood, 2011, 118, 1534-1534.	1.4	5
198	Clinical outcomes of second relapsed and refractory first relapsed paediatric AML : A retrospective study within the NOPHOâ€ÐB SHIP consortium. British Journal of Haematology, 2022, , .	2.5	5

#	Article	IF	Citations
199	Acute lymphoblastic leukemia with Philadelphia chromosome in a 39-year-old woman with Down syndrome presenting as meningitis and fulminant liver failure. Leukemia Research, 2010, 34, e297-e299.	0.8	4
200	Tubulointerstitial Nephritis in a Patient With Probable Autoimmune Lymphoproliferative Syndrome. Journal of Pediatric Hematology/Oncology, 2013, 35, e187-e189.	0.6	4
201	Acute renal failure and normal blood count: A rare presentation of T-cell acute lymphoblastic leukemia. Leukemia Research Reports, 2014, 3, 14-16.	0.4	4
202	Measuring childhood cancer late effects: evidence of a healthy survivor effect. European Journal of Epidemiology, 2017, 32, 1089-1096.	5.7	4
203	Liver diseases in Adult Life after Childhood Cancer in Scandinavia (ALiCCS): A populationâ€based cohort study of 32,839 oneâ€year survivors. International Journal of Cancer, 2018, 142, 702-708.	5.1	4
204	What Is Abnormal in Normal Karyotype Acute Myeloid Leukemia in Children? Analysis of the Mutational Landscape and Prognosis of the TARGET-AML Cohort. Genes, 2021, 12, 792.	2.4	4
205	JMML Revisited: Role Und Outcome of Hematopoietic Stem Cell Transplantation in Subtypes of Juvenile Myelomonocytic Leukemia (JMML). Blood, 2012, 120, 955-955.	1.4	4
206	Musculoskeletal Diagnoses before Cancer in Children: A Danish Registry-Based Cohort Study. Journal of Pediatrics, 2022, 242, 32-38.e2.	1.8	4
207	Kidney disease in very longâ€term survivors of Wilms tumor: A nationwide cohort study with sibling controls. Cancer Medicine, 2023, 12, 1330-1338.	2.8	4
208	Low frequency of type-I and type-II aberrations in myeloid leukemia of Down syndrome, underscoring the unique entity of this disease. Haematologica, 2012, 97, 632-634.	3.5	3
209	Treatment-related Myelodysplastic Syndrome in a Child With Acute Myeloid Leukemia and TPMT Heterozygosity. Journal of Pediatric Hematology/Oncology, 2015, 37, e242-e244.	0.6	3
210	Lack of splice factor and cohesin complex mutations in pediatric myelodysplastic syndrome. Haematologica, 2016, 101, e479-e481.	3.5	3
211	Children with lowâ€risk acute lymphoblastic leukemia are at highest risk of second cancers. Pediatric Blood and Cancer, 2017, 64, e26518.	1.5	3
212	Diseaseâ€specific hospitalizations among 5â€year survivors of Wilms tumor: A Nordic populationâ€based cohort study. Pediatric Blood and Cancer, 2021, 68, e28905.	1.5	3
213	Abdominal Complications During Treatment for Pediatric Acute Myeloid Leukemia. Journal of Pediatric Hematology/Oncology, 2021, Publish Ahead of Print, .	0.6	3
214	Somatic Disease in Survivors of Childhood Malignant Bone Tumors in the Nordic Countries. Cancers, 2021, 13, 4505.	3.7	3
215	Gemtuzumab Ozagamicin Is Well Tolerated as Post-Consolidation Therapy in Childhood AML.. Blood, 2007, 110, 4367-4367.	1.4	3
216	High Frequency of GATA1 Mutations in Childhood Non-Down Syndrome Acute Megakaryoblastic Leukemia. Blood, 2012, 120, 888-888.	1.4	3

#	Article	IF	Citations
217	Impact of Somatic Mutations on the Outcome of Children and Adolescents with Therapy-Related Myelodysplastic Syndrome. Blood, 2016, 128, 3162-3162.	1.4	3
218	Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS. Haematologica, 2022, 107, 759-764.	3.5	3
219	Hematological Changes Mimicking Myelodysplastic Syndrome Following Treatment for Osteosarcoma. Journal of Pediatric Hematology/Oncology, 2015, 37, 170-174.	0.6	2
220	Brentuximab vedotin monotherapy is an effective treatment in a frail pediatric patient with Down syndrome and classical Hodgkin lymphoma. Pediatric Blood and Cancer, 2020, 67, e28082.	1.5	2
221	Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset. Data in Brief, 2020, 32, 106227.	1.0	2
222	A frameshift variant in specificity protein 1 triggers superactivation of Sp1-mediated transcription in familial bone marrow failure. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 17151-17155.	7.1	2
223	Temporal changes in the probability of live birth among female survivors of childhood cancer: A populationâ€based Adult Life After Childhood Cancer in Scandinavia (ALiCCS) study in five nordic countries. Cancer, 2021, 127, 3881-3892.	4.1	2
224	Measurable Residual Disease Monitoring of SPAG6, ST18, PRAME, and XAGE1A Expression in Peripheral Blood May Detect Imminent Relapse in Childhood Acute Myeloid Leukemia. Journal of Molecular Diagnostics, 2021, 23, 1787-1799.	2.8	2
225	The variable biological signature of refractory cytopenia of childhood (RCC), a retrospective EWOG-MDS study. Leukemia Research, 2021, 108, 106652.	0.8	2
226	Germline Mutations in CBL Cause a Predisposition to Juvenile Myelomonocytic Leukemia.. Blood, 2009, 114, 310-310.	1.4	2
227	Risk-Group Stratified and Minimal Residual Disease (MRD)-Guided Treatment with Extended ATRA and Reduced-Anthracycline Chemotherapy in Childhood Acute Promyelocytic Leukemia (APL): Results from ICC APL Study 01 (NCT01226303; EudraCT 2008-002311-40). Blood, 2015, 126, 563-563.	1.4	2
228	Clinical Impact of Additional Cytogenetic Aberrations and Complex Karyotype In Pediatric 11q23/MLL-Rearranged AML: Results from an International Retrospective Study. Blood, 2010, 116, 762-762.	1.4	2
229	Impact of Allogeneic Hematopoietic Stem Cell Transplantation in First Complete Remission and Additional Cytogenetic Aberrations at Diagnosis on Prognosis in 1256 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia: A Retrospective Study By the I-BFM-SG. Blood, 2021, 138, 2360-2360.	1.4	2
230	Global Phase 3, Randomized, Placebo-Controlled Trial with Open-Label Extension Evaluating the Oral CXCR4 Antagonist Mavorixafor in Patients with WHIM Syndrome (4WHIM): Trial Design and Enrollment. Blood, 2021, 138, 4310-4310.	1.4	2
231	Efficacy, Safety, and Pharmacokinetics (PK) of Azacitidine (AZA) in Children and Young Adults with Acute Myeloid Leukemia (AML) in the Phase 2 AZA-AML-004 Trial. Blood, 2020, 136, 10-11.	1.4	2
232	Immunophenotypically defined stem cell subsets in paediatric <scp>AML</scp> are highly heterogeneous and demonstrate differences in <scp>BCL</scp>â€2 expression by cytogenetic subgroups. British Journal of Haematology, 2022, 197, 452-466.	2.5	2
233	Integrative Neuromuscular Training in Adolescents and Children Treated for Cancer (INTERACT): Study Protocol for a Multicenter, Two-Arm Parallel-Group Randomized Controlled Superiority Trial. Frontiers in Pediatrics, 2022, 10, 833850.	1.9	2
234	Long-Term Risk of Hospitalization for Somatic Diseases Among Survivors of Childhood Acute Lymphoblastic Leukemia. JNCI Cancer Spectrum, 0, , .	2.9	2

#	Article	IF	Citations
235	SIGNIFICANCE OF MONOSOMY 7 IN MYELOID LEUKEMIAS IN CHILDREN. Fetal and Pediatric Pathology, 2000, 19, 235-250.	0.3	1
236	Splenectomy in two children with autoimmune lymphoproliferative syndrome and massive splenomegaly. Pediatric Blood and Cancer, 2009, 53, 1124-1126.	1.5	1
237	Hospital admission for neurologic disorders among 5â€year survivors of noncentral nervous system tumors in childhood: A cohort study within the Adult Life after Childhood Cancer in Scandinavia study. International Journal of Cancer, 2020, 146, 819-828.	5.1	1
238	Risk of late health effects after soft-tissue sarcomas in childhood â€“ a population-based cohort study within the Adult Life after Childhood Cancer in Scandinavia research programme. Acta OncolÃ³gica, 2020, 59, 1246-1256.	1.8	1
239	Hospitalizations in longâ€term survivors of childhood <scp>AML</scp> treated with allogeneic <scp>HCT</scp>â€”An Adult Life after Childhood Cancer in Scandinavia (<scp>ALiCCS</scp>) study. American Journal of Hematology, 2021, 96, E74-E77.	4.1	1
240	Esophageal disease among childhood cancer survivorsâ€”A report from the Childhood Cancer Survivors Study. Pediatric Blood and Cancer, 2021, 68, e29043.	1.5	1
241	Factors influencing participation rates in clinical lateâ€effect studies of childhood cancer survivors. Pediatric Blood and Cancer, 2021, 68, e29098.	1.5	1
242	Myelodysplastic syndrome. , 0, , 548-570.		1
243	Long Non-Coding RNAs As Novel Therapeutic Targets in Juvenile Myelomonocytic Leukemia: Proof of Concept Study. Blood, 2019, 134, 1701-1701.	1.4	1
244	Integrative Analysis of Pediatric Acute Leukemia Identifies Immature Subtypes That Span a T Lineage and Myeloid Continuum with Distinct Prognoses. Blood, 2019, 134, 918-918.	1.4	1
245	Outcome of (Novel) Subgroups in 1257 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia (AML) and the Significance of Minimal Residual Disease (MRD) Status: A Retrospective Study By the I-BFM-SG. Blood, 2020, 136, 26-27.	1.4	1
246	NF1 Tumor Suppressor Gene Inactivation in Juvenile Myelomonocytic Leukemia: New Genetic Evidence and Consequences for Diagnostic Work-up. Blood, 2020, 136, 30-31.	1.4	1
247	Impact of Minimal Residual Disease (MRD) Assessed before Transplantation on the Outcome of Children with Acute Myeloid Leukemia Given an Allograft: A Retrospective Study By the I-BFM Study Group. Blood, 2020, 136, 38-39.	1.4	1
248	Hyperdiploidy in Childhood AML Associated with Low Age and AML-M7. A NOPHO-AML Study and Literature Review,. Blood, 2011, 118, 3529-3529.	1.4	1
249	Mutation Analysis of JAK-1, 2 and 3 in Children with Down Syndrome and Acute Leukemia.. Blood, 2009, 114, 5035-5035.	1.4	1
250	Turner Syndrome and Myelodysplastic Syndrome. No Reason to Alert. Journal of Pediatric Hematology/Oncology, 1997, 19, 179.	0.6	1
251	Effect of Age and Weight on Toxicity and Survival in Pediatric Acute Myeloid Leukemia. Blood, 2015, 126, 3745-3745.	1.4	1
252	Predictors of Early Death in Childhood Acute Promyelocytic Leukemia: Results of an International Retrospective Study. Blood, 2015, 126, 172-172.	1.4	1

#	Article	IF	Citations
253	Hypodiploidy in Childhood Acute Myeloid Leukemia: A Retrospective Cohort Study within the International Berlin-Frankfurt-MÃ¼nster Study Group. Blood, 2018, 132, 1466-1466.	1.4	1
254	M-ficolin: a valuable biomarker to identify leukaemia from juvenile idiopathic arthritis. Archives of Disease in Childhood, 2022, 107, 371-376.	1.9	1
255	The Molecular Characteristics and Clinical Relevance of NUP98-Other Translocations in Pediatric Acute Myeloid Leukemia. Blood, 2020, 136, 36-37.	1.4	1
256	SIGNIFICANCE OF MONOSOMY 7 IN MYELOID LEUKEMIAS IN CHILDREN. Fetal and Pediatric Pathology, 2000, 19, 235-250.	0.3	1
257	Reply to Gassas et al. Leukemia, 2003, 17, 2532-2532.	7.2	0
258	Myelodysplastic syndrome. , 0, , 429-443.		0
259	Extreme hyperleukocytosis in a pediatric T-ALL patient with a rare translocation, t(7;19)(q35;p13), and submicroscopic deletions at 4q25, 7q33 and 10q23. Leukemia Research Reports, 2014, 3, 4-7.	0.4	0
260	Hearing Status in Survivors of Childhood Acute Myeloid Leukemia Treated With Chemotherapy Only: A NOPHO-AML Study. Journal of Pediatric Hematology/Oncology, 2019, 41, e12-e17.	0.6	0
261	Treatment of Molecular Relapse by Cessation of Immunosuppression After Hematopoietic Stem Cell Transplantation in Pediatric FLT3-ITD AML Monitored by WT1 Expression in Peripheral Blood. Journal of Pediatric Hematology/Oncology, 2019, 41, 417-419.	0.6	0
262	Subcutaneous Anti-D as Treatment of Idiopathic Thrombocytopenic Purpura in Children; Clinical Observations.. Blood, 2005, 106, 3998-3998.	1.4	0
263	A Complex Karyotype but Not Monosomy 7 Is an Independent Prognostic Factor in Advanced Childhood MDS.. Blood, 2007, 110, 2452-2452.	1.4	0
264	Impaired CD163 Mediated Hemoglobin-Scavenging and Hemolytic Crisis in Patients Treated with CD33 Targeted Chemotherapy (Gemtuzumab Ozogamicin, Mylotargâ„¢).. Blood, 2007, 110, 3684-3684.	1.4	0
265	BRAF Mutations in Juvenile Myelomonocytic Leukemia.. Blood, 2007, 110, 4602-4602.	1.4	0
266	Mathematical Modeling of Molecular Relapse Kinetics in NPM1c+, PML-Rara+, RUNX1-RUN1T1+, and CBFB-MYH11+ Acute Myeloid Leukemias. Blood, 2008, 112, 2525-2525.	1.4	0
267	High Frequency of Copy Number Variations in Myeloid Leukemia of Down Syndrome.. Blood, 2009, 114, 3242-3242.	1.4	0
268	Genetic and Epigenetic Events in Childhood AML - Similarities and Differences with Adult AML.. Blood, 2009, 114, 2396-2396.	1.4	0
269	Aberrant DNA Methylation Characterizes a Subtype of Juvenile Myelomonocytic Leukemia (JMML) with Poor Outcome.. Blood, 2009, 114, 828-828.	1.4	0
270	Myeloid Leukemia of Down Syndrome: The Results of An International Retrospective Study. Blood, 2010, 116, 2718-2718.	1.4	0

#	Article	IF	Citations
271	Good General Health In Survivors of Childhood AML Treated with Chemotherapy Only: A NOPHO-AML Study.. Blood, 2010, 116, 1076-1076.	1.4	0
272	JMML and Myelodysplastic Syndrome in Children. , 2011, , 253-278.		0
273	IER3 Expression in Childhood Myelodysplastic Syndrome,. Blood, 2011, 118, 3817-3817.	1.4	0
274	Mutations of the Spliceosome Complex Genes Occur In Adult Patients but Are Very Rare In Children with Myeloid Neoplasia. Blood, 2011, 118, 2797-2797.	1.4	0
275	Therapy-Related Myelodysplastic Syndrome Following Treatment for Childhood Acute Lymphoblastic Leukemia: Outcome of Patients Registered in the EWOG-MDS 98/06 Studies,. Blood, 2011, 118, 4130-4130.	1.4	0
276	Molecular Aberrations in 107 Children with Myelodysplastic Syndrome (MDS).. Blood, 2012, 120, 2802-2802.	1.4	0
277	Pediatric Acute Myeloid Leukemia with t(8;16)(p11;p13): A Distinct Clinical and Biological Entity. Results of a Collaborative Study by the International Berlin-Frankfurt-Mul̂nster AML Study Group.. Blood, 2012, 120, 2516-2516.	1.4	0
278	The Applicability Of The WHO Classification In Pediatric AML. A NOPHO-AML Study. Blood, 2013, 122, 1354-1354.	1.4	0
279	Pediatric Acute Megakaryoblastic Leukemia without Down Syndrome: A Retrospective Study by the International Berlin-Frankfurt-Munster Study Group (I-BFMSG). Blood, 2014, 124, 3670-3670.	1.4	0
280	Bone Marrow Immunophenotyping By Flow Cytometry in Refractory Cytopenia of Childhood. Blood, 2014, 124, 1916-1916.	1.4	0
281	The Integrated Immunological Signature of Refractory Cytopenia of Childhood (RCC). Blood, 2015, 126, 1657-1657.	1.4	0
282	qPCR MRD Monitoring in Peripheral Blood May Predict Hematological Relapse in Pediatric Acute Myeloid Leukemia. Blood, 2015, 126, 3749-3749.	1.4	0
283	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Children and Adolescents with GATA2-Related Myelodysplastic Syndrome. Blood, 2019, 134, 2033-2033.	1.4	0
284	Patient-Tailored Deep Sequencing of Peripheral Blood Enables Early Detection of Relapse in Childhood Acute Myeloid Leukemia. Blood, 2019, 134, 1456-1456.	1.4	0
285	Patient-Tailored Measurable Residual Disease Monitoring in Peripheral Blood Using Deep Sequencing and Droplet Digital PCR for Early Detection of Relapse in Childhood Acute Myeloid Leukemia: A NOPHO-DBH Collaborative Study. Blood, 2021, 138, 3457-3457.	1.4	0
286	Title is missing!. , 2020, 16, e1009231.		0
287	Title is missing!. , 2020, 16, e1009231.		0
288	Title is missing!. , 2020, 16, e1009231.		0

#	Article	IF	Citations
289	Title is missing!. , 2020, 16, e1009231.		0
290	Effects on Pediatric Cancer Survivors: The FAMily-Oriented Support (FAMOS) Randomized Controlled Trial. Journal of Pediatric Psychology, 0, , .	2.1	0